![](/images/graphics-bg.png)
Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East
المؤلفون المشاركون
Hammoudeh, Mohammed
Al Awadhi, Adel
Akhlaghi, Maassoumeh
Ahmadzadeh, Arman
Sadeghi Abdollahi, Bahar
Hasan, Eman A.
المصدر
International Journal of Rheumatology
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-05-19
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
This open-label study investigated the safety and efficacy of tocilizumab in Middle Eastern patients with rheumatoid arthritis (RA).
Patients whose Disease Activity Score based on 28 joints (DAS28) was >3.2 received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
Patients receiving aTNF ± nonbiologic disease-modifying antirheumatic drug(s) (DMARD(s)) switched to tocilizumab; patients receiving nonbiologic DMARD monotherapy added tocilizumab.
Primary end points were adverse events (AEs), serious AEs (SAEs), and laboratory parameters; secondary end points were DAS28, Health Assessment Questionnaire-Disability Index, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
Eighty-eight of 95 patients completed 24 weeks.
Overall, 125 AEs were reported in 43 (45%) patients; the most common were increased hepatic enzymes (16%) and cholesterol (11%).
Eight patients experienced SAEs.
Significant changes from baseline to week 24 occurred for hemoglobin, neutrophils, platelets, total cholesterol, and liver enzymes (P<0.05).
DAS28, CRP, and ESR decreased significantly from baseline at each visit (P<0.0001).
At week 24, the proportions of patients reporting DAS28 clinically meaningful improvement (decrease ≥1.2), low disease activity (DAS28 ≥2.6 to ≤3.2), and remission (DAS28 <2.6) were 92%, 23%, and 64%, respectively.
Safety and efficacy of tocilizumab were consistent with values reported in Western patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hammoudeh, Mohammed& Al Awadhi, Adel& Hasan, Eman A.& Akhlaghi, Maassoumeh& Ahmadzadeh, Arman& Sadeghi Abdollahi, Bahar. 2015. Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East. International Journal of Rheumatology،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1066898
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hammoudeh, Mohammed…[et al.]. Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East. International Journal of Rheumatology No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1066898
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hammoudeh, Mohammed& Al Awadhi, Adel& Hasan, Eman A.& Akhlaghi, Maassoumeh& Ahmadzadeh, Arman& Sadeghi Abdollahi, Bahar. Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East. International Journal of Rheumatology. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1066898
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1066898
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)